News Sentiment

COR sentiment intelligence

Cencora Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 51 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Distribution Read-through group
Latest close 303.44 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend inactive

+2.3% over one week, +7.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Cencora stock reflects steady healthcare distribution role as investors track U.S. drug spending tre

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 2.3% Price confirming higher
Trend fit Trend inactive 7.7% over four weeks
Fair value 17.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 28
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Ad Hoc News 10
Market source 9
TradingView 7
Simply Wall Street 4
Stock Titan 4
simplywall.st 4
MarketWatch 3
Morningstar 3

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 14
Macro sensitivity 4
Analyst action 3
Balance sheet 2
Guidance 1
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Ad Hoc News Direct company coverage

Cencora stock reflects steady healthcare distribution role as investors track U.S. drug spending tre

Cencora Inc. plays a crucial role in the U.S. pharmaceutical supply chain as one of the largest distributors of drugs to healthcare providers. The company's business model is characterized by high volumes, tight logistics, and thin per-unit margins, making efficiency paramount. I

Tone
Positive 67/100
Event
Macro sensitivity
Published
16 Jul 2026 10:50
Source
Ad Hoc News
MarketWatch Direct company coverage

Cencora Inc. stock underperforms Wednesday when compared to competitors

Cencora Inc. (COR) stock fell 1.89% to $296.57 on Wednesday, underperforming the broader market which saw the S&P 500 and Dow Jones Industrial Average rise. This marks the second consecutive day of losses for the company's stock.

Tone
Negative 28/100
Event
Market update
Published
15 Jul 2026 20:47
Source
MarketWatch
Simply Wall Street Direct company coverage

How Cencora’s Revenue Miss Amid Growth Will Impact Cencora (COR) Investors

Cencora (COR) reported past-quarter revenues of US$78.36 billion, a 3.8% year-on-year increase, but missed analyst expectations by 3.9%. This revenue miss, despite overall growth, raises questions about the company's ability to maintain its valuation amidst margin pressures and e

Tone
Negative 37/100
Event
Earnings
Published
15 Jul 2026 19:07
Source
Simply Wall Street
TradingView Direct company coverage

ABC4571978 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Cencora, Inc. bond ABC4571978, detailing its interest rate and payment schedule. The bond has a current coupon rate of 4.30%, with the next payment planned for December 15, 2026. It offers additional details on past and upcoming payo

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 19:07
Source
TradingView
TradingView Direct company coverage

ABGB Bond Profile — Key Metrics

This article provides key metrics for the ABGB bond, issued by Cencora, Inc. The bond is a 3.45% security maturing on December 15, 2027, with an outstanding amount of $750 million. Cencora, Inc. is a pharmaceutical sourcing and distribution company, operating through U.S. and Int

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 12:08
Source
TradingView
TradingView Direct company coverage

ABC6310085 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the ABC6310085 bond issued by Cencora, Inc. The bond has a coupon rate of 5.65% with the next payment scheduled for August 13, 2026. It highlights the availability of detailed coupon data including rates and payment schedules for investo

Tone
Neutral 50/100
Event
Macro sensitivity
Published
15 Jul 2026 11:37
Source
TradingView
Ad-hoc-news.de Direct company coverage

Cencora stock reflects steady growth as healthcare distribution evolves

Cencora Inc. (ISIN US15135B1017) is a major US healthcare services company, providing pharmaceutical distribution and logistics. The company's stock reflects its crucial role in the supply chain, facilitating the movement of drugs from manufacturers to healthcare providers and of

Tone
Positive 81/100
Event
Macro sensitivity
Published
14 Jul 2026 23:19
Source
Ad-hoc-news.de
TradingView Direct company coverage

US3073EAT2 Bond Risk Profile

This page provides an overview of the US3073EAT2 bond issued by Cencora, Inc., maturing on March 15, 2031, with a 2.7% coupon rate. It focuses on the bond's risk profile, offering key metrics for credit risk assessment such as security level, inflation protection, and issuer rati

Tone
Neutral 50/100
Event
Balance sheet
Published
14 Jul 2026 21:38
Source
TradingView
MarketWatch Direct company coverage

Cencora Inc. stock underperforms Tuesday when compared to competitors

Cencora Inc. (COR) shares dropped 1.26% on Tuesday, closing at $302.28, despite a positive trading day for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains. This decline broke Cencora's two-day winning streak.

Tone
Negative 37/100
Event
Market update
Published
14 Jul 2026 16:47
Source
MarketWatch
TradingView Direct company coverage

ABC4987224 Bond Risk Profile

This page provides a risk profile for the ABC4987224 bond issued by Cencora, Inc., maturing on May 15, 2030, with a 2.8% coupon. It offers an overview of the bond's features, credit risk assessment metrics like security level and issuer rating, and access to analyst ratings. The

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 15:37
Source
TradingView
Simply Wall Street Direct company coverage

Cencora (COR) Following Soft Earnings Is The Stock Starting To Look Undervalued

Cencora (COR) reported quarterly revenue of $78.36 billion, up 3.8% year-on-year but below consensus forecasts. Despite recent share price gains, the stock is down 9.66% year to date but has a 5-year total shareholder return of 186.24%. The company is considered 12.7% undervalued

Tone
Positive 64/100
Event
Earnings
Published
14 Jul 2026 15:32
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Cencora : World Courier Expands Cold Chain Capabilities | Cencora

Cencora's World Courier has expanded its cold chain capabilities. This news is distributed via Public Technologies and focuses on the company's efforts to enhance its pharmaceutical distribution services, particularly for temperature-sensitive products. The article mentions Cenco

Tone
Positive 66/100
Event
Market update
Published
14 Jul 2026 12:53
Source
www.marketscreener.com
Ad Hoc News Direct company coverage

Cencora stock reflects steady growth in pharmaceutical distribution and services

Cencora Inc. (ISIN US15135B1017) is a key player in the US pharmaceutical distribution and healthcare services sector, with its stock performance linked to growth in drug spending, specialty therapies, and supply-chain efficiency. The company's strategy emphasizes scale, data-dri

Tone
Positive 74/100
Event
Market update
Published
14 Jul 2026 00:45
Source
Ad Hoc News
TradingView Direct company coverage

ABC4987224 Bond Profile — Key Metrics

This article provides key financial metrics for the ABC4987224 bond issued by Cencora, Inc. The bond has a 2.8% coupon rate and matures on May 15, 2030, with an outstanding amount of $500 million. Cencora, Inc. is a pharmaceutical sourcing and distribution services company operat

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 23:37
Source
TradingView
Ad Hoc News Direct company coverage

Cencora stock reflects steady healthcare distribution role in a complex market

Cencora Inc. plays a crucial role in the U.S. pharmaceutical supply chain as a large-scale distributor and services provider. The company's business model relies on high revenue volumes with thin margins, driven by efficient logistics, strong customer relationships, and expansion

Tone
Positive 66/100
Event
Earnings
Published
13 Jul 2026 10:37
Source
Ad Hoc News
Simply Wall Street Direct company coverage

Cencora (COR) Stock Still Looks Undervalued On Cash Flow And Earnings

Cencora (COR) stock appears undervalued based on its discounted cash flow (DCF) intrinsic value estimate and P/E ratio comparison. The DCF model suggests a 39.6% discount, while the P/E of 23.2x is below the healthcare sector average and a tailored benchmark. Investors should con

Tone
Positive 72/100
Event
Earnings
Published
12 Jul 2026 22:37
Source
Simply Wall Street
TradingView Direct company coverage

ETFs Investing in Cencora, Inc. Stocks

This article provides a list of Exchange Traded Funds (ETFs) that hold shares of Cencora, Inc. The ETFs are sorted by their market value and include details such as weight in the fund, issuer, management style, expense ratio, assets under management (AUM), price, change percentag

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 19:07
Source
TradingView
Ad Hoc News Direct company coverage

Cencora stock trades steadily as healthcare distribution scale supports long-term growth

Cencora Inc. plays a crucial role as a major U.S. healthcare distributor, focusing on pharmaceutical distribution, logistics, and related services, which are critical for connecting manufacturers, pharmacies, and healthcare providers. The company's stable demand in the healthcare

Tone
Positive 71/100
Event
Macro sensitivity
Published
10 Jul 2026 07:32
Source
Ad Hoc News
MarketWatch Direct company coverage

Cencora Inc. stock underperforms Thursday when compared to competitors

Cencora Inc. (COR) shares dropped 2.30% to $302.46 on Thursday, despite a strong day for the broader stock market, which saw the S&P 500 Index and Dow Jones Industrial Average rise. This decline ended a six-day winning streak for the stock.

Tone
Negative 30/100
Event
Market update
Published
09 Jul 2026 20:46
Source
MarketWatch
Morningstar Direct company coverage

Cardinal's Growth Momentum Looks Strong From Prescription Trends, Specialty Investments, and GLP-1s

Cardinal Health, a major player in pharmaceutical distribution, is experiencing strong growth. This momentum is attributed to favorable prescription trends, strategic investments in specialty pharmaceuticals, and the rising impact of GLP-1 drugs. The company, alongside Cencora an

Tone
Positive 62/100
Event
Market update
Published
09 Jul 2026 20:08
Source
Morningstar
Morningstar Direct company coverage

Pricing Headwinds and Industry Trends Cut Into Cencora's 2026 Sales, but Fundamentals Remain Strong

Cencora, a key player in the pharmaceutical wholesale and distribution market, is facing pricing headwinds and industry trends that are projected to impact its 2026 sales figures. Despite a recent guidance cut and stock selloff, the company's fundamental business strategy and out

Tone
Neutral 50/100
Event
Guidance
Published
09 Jul 2026 20:08
Source
Morningstar
Morningstar Direct company coverage

McKesson's Oncology Leadership and Robust Free Cash Flow Underpin Strong Durable Fundamentals

McKesson, a major pharmaceutical wholesaler, benefits from its leadership in oncology and strong free cash flow, contributing to its durable fundamentals. The company, along with Cardinal Health and Cencora, forms an oligopoly that distributes over 90% of the U.S. pharmaceutical

Tone
Positive 66/100
Event
Balance sheet
Published
09 Jul 2026 19:42
Source
Morningstar
Simply Wall Street Direct company coverage

Cencora (NYSE:COR) Stock Forecast & Analyst Predictions

Cencora (NYSE:COR) is projected to grow earnings by 5.9% and revenue by 5.6% annually, with EPS expected to increase by 9.2% per annum and a forecast return on equity of 53.8% in three years. Recent updates include increased EPS estimates for fiscal year 2026, though revenue outl

Tone
Positive 64/100
Event
Earnings
Published
09 Jul 2026 07:07
Source
Simply Wall Street